<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00606359</url>
  </required_header>
  <id_info>
    <org_study_id>GID26</org_study_id>
    <nct_id>NCT00606359</nct_id>
  </id_info>
  <brief_title>Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects</brief_title>
  <official_title>Immunogenicity of the Inactivated Split-Virion Influenza Vaccine Administered by the Intradermal Route in Renal Transplant Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To describe the immunogenicity of an injection of the investigational inactivated,&#xD;
      split-virion influenza vaccine 21 days after vaccination in 18 to 60 years old renal&#xD;
      transplant subjects identified as non-responder to previous vaccination with the IM reference&#xD;
      vaccine (Vaxigrip®).&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      To describe the safety of an injection of the investigational inactivated, split-virion&#xD;
      influenza vaccine in 18 to 60 years old renal transplant subjects identified as non-responder&#xD;
      to previous vaccination with the IM reference vaccine&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is a multicenter, randomized, controlled trial in renal transplant subjects aged 18&#xD;
      to 60 years who are non-responders to vaccination with the reference vaccine. Subjects will&#xD;
      be randomized to receive either the 2007-2008 15 µg investigational vaccine or the 2007-2008&#xD;
      IM reference vaccine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-HA individual titers</measure>
    <time_frame>21 Days Post-vaccination 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Individual titers ratio</measure>
    <time_frame>21 Days Post-vaccination 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion or significant increase</measure>
    <time_frame>21 Days Post-vaccination 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Adverse events in the first 21 days after each vaccination; Pre-listed reactions in the 7 days following each vaccination; Serious adverse events during the entire trial.</measure>
    <time_frame>21 days following each vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Influenza</condition>
  <condition>Orthomyxoviridae Infections</condition>
  <arm_group>
    <arm_group_label>Study Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated, split-virion influenza virus</intervention_name>
    <description>0.1 mL, Intradermal. 2 vaccinations 12 months apart</description>
    <arm_group_label>Study Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated, split-virion influenza virus</intervention_name>
    <description>0.5 mL, Intramuscular. 2 vaccinations, 12 months apart</description>
    <arm_group_label>Study Group 2</arm_group_label>
    <other_name>Vaxigrip®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to attend all scheduled visits and to comply with all trial procedures.&#xD;
&#xD;
          -  Subject with renal transplant for at least 6 months.&#xD;
&#xD;
          -  Subject with stable renal function, i.e. with a variation of creatinin value &lt; 20% and&#xD;
             with a creatinin clearance estimated according to Cockroft and Gault calculation &gt; 20&#xD;
             mL/min during the 3 months preceding inclusion.&#xD;
&#xD;
          -  Aged 18 to 59 years on the day of the screening visit.&#xD;
&#xD;
          -  Informed Consent Form signed.&#xD;
&#xD;
          -  Subject entitled to national social security.&#xD;
&#xD;
          -  Subject under immunosuppressive therapy.&#xD;
&#xD;
          -  For a woman, inability to bear a child or negative urine pregnancy test.&#xD;
&#xD;
          -  Subject non-responder to previous IM vaccination with the 2006-2007 Northern&#xD;
             Hemisphere Vaxigrip® formulation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with sign of transplanted kidney reject within 3 months preceding vaccination&#xD;
             according to medical practice.&#xD;
&#xD;
          -  Systemic hypersensitivity to any of the vaccine components or history of a&#xD;
             life-threatening reaction to the trial vaccine or a vaccine containing the same&#xD;
             substances.&#xD;
&#xD;
          -  Febrile illness (oral temperature ≥ 37.5°C, or rectal equivalent temperature ≥ 38.0°C)&#xD;
             on the day of inclusion.&#xD;
&#xD;
          -  Breast-feeding.&#xD;
&#xD;
          -  Participation in another clinical trial in the 4 weeks preceding the trial&#xD;
             vaccination.&#xD;
&#xD;
          -  Planned participation in another clinical trial during the present trial period.&#xD;
&#xD;
          -  Congenital immunodeficiency, anti-cancer chemotherapy or radiation therapy within the&#xD;
             preceding 6 months.&#xD;
&#xD;
          -  Chronic illness, except renal failure or renal disorders, at a stage that could&#xD;
             interfere with trial conduct or completion.&#xD;
&#xD;
          -  Current abuse of alcohol or drug addiction that may interfere with the subject's&#xD;
             ability to comply with trial procedures.&#xD;
&#xD;
          -  Blood or blood-derived products received in the past 3 months .&#xD;
&#xD;
          -  Any vaccination in the 4 weeks preceding the trial vaccination.&#xD;
&#xD;
          -  Vaccination planned in the 4 weeks following the trial vaccination.&#xD;
&#xD;
          -  Thrombocytopenia or bleeding disorder contraindicating intramuscular (IM) vaccination&#xD;
&#xD;
          -  Previous vaccination against influenza in the preceding 6 months.&#xD;
&#xD;
          -  Subject deprived of freedom by an administrative or court order, or in an emergency&#xD;
             setting, or hospitalized without his/her consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lyon, Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>January 21, 2008</study_first_submitted>
  <study_first_submitted_qc>January 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2008</study_first_posted>
  <last_update_submitted>January 10, 2014</last_update_submitted>
  <last_update_submitted_qc>January 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Orthomyxoviridae Infections</keyword>
  <keyword>Renal Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Orthomyxoviridae Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

